Oncology

Endometrial biopsy
#AstraZeneca #European Commission #Immunotherapy #Oncology #PARP inhibitors #Phase III trial

Lynparza and Imfinzi combination approved in the EU for endometrial cancer

AstraZeneca’s Imfinzi (durvalumab) and Lynparza (olaparib) have been approved in the European Union (EU) as treatment for certain patients with primary advanced or recurrent endometrial cancer. Imfinzi plus chemotherapy as first-line treatment followed by Lynparza and Imfinzi has been approved for patients with mismatch repair proficient (pMMR) disease. Imfinzi plus… Read More

#News #Regulatory #Trending News

CAR-T therapy
#Biosyngen #CAR-T #Cell therapy #FDA #Head and neck cancer #Oncology #Solid tumours

CAR-T therapy for nasopharyngeal cancer enters Phase II trials

The US Food and Drug Administration (FDA) has approved a Phase II clinical trial for Biosyngen’s BRG01, an EBV-specific CAR-T cell therapy. This marks the first cell therapy to enter Phase lI trials in both the US and China for the treatment of relapsed/metastatic EBV-positive nasopharyngeal carcinoma. The Center for… Read More

#News #Regulatory

#Absci #Artificial intelligence (AI) #Collaboration #Generative AI #Oncology #The Memorial Sloan Kettering Cancer Center

Partners use generative AI to develop novel cancer therapeutics

The Memorial Sloan Kettering Cancer Center (MSK) will be collaborating with Absci Corporation to discover and develop novel cancer therapeutics using generative artificial intelligence (AI) for up to six programmes. Under the terms of the collaboration, Absci and MSK’s cancer research teams will co-develop therapeutics using… Read More

#Cancer Research #News

Human liver
#Liver cancer #National Cancer Institute #Oncology #Statins

Cholesterol-lowering drugs reduce liver cancer risk by 30%

In a new study of non-statin cholesterol-lowering medications, cholesterol absorption inhibitors were linked to lower risks of liver cancer. Cholesterol absorption inhibitors, bile acid sequestrants, fibrates, niacin, and omega-3 fatty acids are types of non-statin cholesterol-lowering medications prescribed to manage cholesterol and lipid levels. The different… Read More

#Cancer Research #News

Antibody drug conjugate
#Angiex #Antibody drug conjugate (ADC) #Oncology #Phase I trial #Solid tumours

Antibody-drug conjugate for solid tumours enters Phase I trials

The first patient has been dosed in a Phase I clinical trial of AGX101, a novel TM4SF1-directed antibody-drug conjugate being developed for the treatment of solid cancers. Developer Angiex is focused on nuclear-delivered antibody-drug conjugates (ND-ADCs), which release therapeutic payloads directly into the nucleus or cytosol,… Read More

#Cancer Research #News

MRI of the brain showing glioblastoma
#Brain cancer #FDA #Oncology #Servier Pharmaceuticals

FDA approves oral therapy for Grade 2 IDH-mutant glioma

The US Food and Drug Administration (FDA) has approved Voranigo, an isocitrate dehydrogenase-1 (IDH1) and isocitrate dehydrogenase-2 (IDH2) inhibitor, indicated for the treatment of patients 12 years and older with Grade 2 astrocytoma or oligodendroglioma. It is approved in patients with a susceptible IDH1 or IDH2 mutation following surgery including… Read More

#News #Regulatory

#Cell therapy #Funding #Japan #Oncology #Shinobi Therapeutics

Shinobi Therapeutics secures $59M grant for iPS-T cell therapy

Shinobi Therapeutics has been awarded up to $59 million in non-dilutive grant funding by the Japanese Agency for Medical Research and Development (AMED). The funds will support the development of Shinobi's lead iPS-T cell programme targeting GPC3+ tumours. Shinobi also announced an extension of its Series A round, bringing the… Read More

#Business & Investment #News

Simon and Vanessa Conn
#Cancer treatment #circular RNAs #Flinders University #Oncology #Personalised medicine #RNA

Harnessing circRNAs could “change the landscape” of cancer therapy

Circular RNAs (circRNAs) have “remarkable potential” to improve cancer treatment and patient outcomes within the next five to 10 years, according to a new study by Flinders University in Australia. The research was led by Senior Researcher Dr Vanessa Conn and Professor Simon Conn, who leads… Read More

#Cancer Research #Editor's Choice #News

Soft tissue sarcoma
#Adaptimmune Therapeutics #Cell therapy #FDA #Oncology #Solid tumours

First engineered cell therapy for a solid tumour gets US approval

Adaptimmune Therapeutics’ Tecelra (afamitresgene autoleucel) has become the first engineered cell therapy for a solid tumour cancer approved in the US. It is also the first new therapy option in more than a decade for synovial sarcoma, which is a rare, soft tissue cancer that most commonly impacts young adults. Read More

#News #Regulatory #Trending News

Child with retinoblastoma
#FDA #Oncology #Paediatrics #Rare disease #Theriva Biologics

Retinoblastoma therapy gets FDA rare paediatric drug designation

Theriva Biologics’ VCN-01 for retinoblastoma has been granted rare paediatric drug designation (RPDD) by the US Food and Drug Administration (FDA). The FDA grants RPDD for rare diseases (fewer than 200,000 affected persons in the United States) that are serious and life-threatening and primarily affect children ages 18 years or… Read More

#News #Regulatory

Fusobacterium
#Bacteria #Guy’s and St Thomas' #Head and neck cancer #King's College London #Oncology

Bacteria destroys head and neck cancer tumours

Researchers at Guy’s and St Thomas’, and King’s College London in the UK have found that a bacteria is toxic for head and neck cancer and could lead to better treatments for patients. Fusobacterium is usually associated with the progression of bowel cancer. However, new research… Read More

#Cancer Research #Editor's Choice #News

#Cancer research #Cancer therapeutics #Haematology #Oncology

New DDW Highlights vodcast: 31 July 2024

Every week, DDW’s Megan Thomas narrates five key stories of the week to keep DDW subscribers up-to-date on the latest industry updates in the DDW Highlights podcast. It is now also available in a concise vodcast format.   There have been some interesting… Read More

#News

Vaccine production
#Cancer vaccine #mRNA #mRNA-based vaccines #Oncology #Personalised medicine #University of Queensland

Personalised cancer vaccines to be produced at Queensland lab

A new facility at The University of Queensland, Australia, will provide researchers with cancer vaccines tailored to individual patients. The lab at UQ’s Australian Institute for Bioengineering and Nanotechnology (AIBN) will bring together the equipment and expertise to enable the design, manufacture and delivery of new… Read More

#News

Cancer cell
#Breast Cancer Now #Oncology #The Institute of Cancer Research #Treatment resistance

Science reveals how cancer cells outsmart normal cells

Scientists have discovered that some cancer cells pretend to be ‘super fit’ to fool normal healthy cells into giving them their nutrients, allowing them to expand and spread around the body. A team from The Institute of Cancer Research (ICR), London, found that ‘cheating’ cancer cells… Read More

#Cancer Research #News #Trending News

Bispecific antibodies
#Bispecific Antibodies #Dren Bio #Novartis #Oncology #Partnership

Novartis and Dren Bio partner on bispecific antibodies for cancer

Dren Bio and Novartis Pharma have entered a strategic collaboration focused on the discovery and development of therapeutic bispecific antibodies for cancer. Under the terms of the agreement, Dren Bio will receive a total upfront consideration of $150 million from Novartis, which includes a $25 million equity investment in the… Read More

#Business & Investment #News